Join the 'Follicular Lymphoma' group to help and get support from people like you. How it works
Follicular Lymphoma Blog
| Tweet |
Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade
Posted 24 Nov 2010 by Drugs.com
WEDNESDAY, Nov. 24 – Clinicians have made remarkable advances in treating blood cancers with bone marrow and blood stem cell transplants in recent years, significantly reducing the risk of treatment-related complications and death, a new study shows. Between the early 1990s and 2007, there was a 41 percent drop in the overall risk of death in an analysis of more than 2,500 patients treated at Fred Hutchinson Cancer Center in Seattle, a leader in the field of blood cancers and other malignancies. Researchers from the Fred Hutchinson Cancer Center, who conducted the study, also noted dramatic decreases in treatment complications such as infection and organ damage. The study was published in the Nov. 24 issue of the New England Journal of Medicine "We have made enormous strides in understanding this very complex procedure and have yielded quite spectacular results," said study senior ... Read more
Related support groups: Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, Follicular Lymphoma, Acute Nonlymphocytic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Chronic Eosinophilic Leukemia
Treatment With Rituxan May Reduce Recurrence of Follicular Lymphoma
Posted 21 May 2010 by Drugs.com
THURSDAY, May 20 – The final phase of a drug study finds that two years of treatment with rituximab (Rituxan) cuts in half the risk that follicular lymphoma patients who respond to chemotherapy will suffer a recurrence of the disease. "These findings provide hope for the way we manage this disease. Rituximab maintenance therapy is likely to become a new standard of care for these patients," study author Dr. Gilles Salles, a professor of medicine at the University of Lyon in France, said in a news release. Typically, he noted, patients often relapse within a few years of their initial treatment. The researchers reached their conclusions after randomly assigning patients with follicular lymphoma to two years of treatment with the drug (505 patients) or no treatment with the drug (513 patients). After a median of 25 months, 34 percent of those who didn't take the treatment had recurrence ... Read more
Related support groups: Rituxan, Rituximab, Follicular Lymphoma